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Acquired metallo-β-lactamases (MBLs) can confer
broad-spectrum β-lactam resistance (including carbapen-
ems) not reversible by conventional β-lactamase inhibitors
and are emerging resistance determinants of remarkable
clinical importance. In 2001, multidrug-resistant
Pseudomonas aeruginosa carrying blaVIM MBL genes were
found to be widespread (approximately 20% of all P. aerug-
inosa isolates and 70% of the carbapenem-resistant iso-
lates) at Trieste University Hospital. Clonal diversity and
heterogeneity of resistance determinants (either blaVIM-1-
like or blaVIM-2-like) were detected among MBL producers.
This evidence is the first that acquired MBLs can rapidly
emerge and establish a condition of endemicity in certain
epidemiologic settings.
B
acterial pathogens bearing acquired metallo-β-lacta-
mase (MBL) genes exhibit a broad-spectrum resist-
ance to β-lactams that is not reversible by
serine-β-lactamase inhibitors (e.g., clavulanate and peni-
cillanic acid sulphones), since MBLs are capable of
hydrolyzing most β-lactams and are not susceptible to
inhibitors. Because of the efficient carbapenemase activity
of these enzymes, the resistance profile of MBL producers
notably includes also carbapenems, which are the β-lac-
tams with the broadest spectrum of activity and are among
the “last resort” drugs for the treatment of gram-negative
nosocomial infections. In addition, MBL producers most
often exhibit resistant phenotype to additional classes of
drugs since they originate nosocomially and acquired
MBL genes typically cluster with other drug resistance
determinants in the variable region of multi-resistance
integrons (1–3). For these reasons, infections caused by
MBL producers can pose a substantial challenge for
antimicrobial chemotherapy. 
The IMPand VIM enzymes are the most common types
of acquired MBLs (2,3). The IMP enzymes were first
reported in Japan (4), while the VIM enzymes were first
reported in Europe (5), but both types of enzymes are now
emerging in Asia, Europe, and the Americas as acquired
resistance determinants in nosocomial isolates of
Enterobacteriaceae,  Pseudomonas aeruginosa,
Acinetobacter spp. and other nonfastidious, gram-negative
nonfermenters (3). The VIM-1 enzyme is 90% amino acid
homologous with the VIM-2 variant and <40% amino acid
homologous with the IMP enzymes (3). Both types of
resistance genes are carried on mobile gene cassettes
inserted into plasmid- or chromosomal-borne integrons, a
location that eventually facilitates horizontal spreading
among different strains (3). 
Thus far, strains with acquired MBLs have usually been
reported sporadically or as causing small nosocomial out-
breaks (4,6–8), while longitudinal surveys have demon-
strated, at most, a low-level endemicity of MBL producers
in hospitals where similar strains have been detected
(9,10). One major hospital outbreak, caused by an MBL-
producing P. aeruginosa clone, was recently reported in
Greece (11). We describe the emergence of high-level-
endemicity for MBL-producing P. aeruginosa, which has
recently occurred in a hospital setting of southern Europe.
The Survey
In the University Hospital of Trieste (northern Italy, at
the border with Slovenia), clinical isolates of P. aeruginosa
producing VIM-type MBLs were detected sporadically, for
the first time, in 1999 (12). In 2001, a significant increase
in the prevalence of imipenem-resistant P. aeruginosa iso-
lates was observed at the Laboratory of Clinical
Microbiology of that hospital (29%, vs. 19% in 2000 and
21% in 1999, respectively; p < 0.001 according to the χ2
test; statistical analyses were conducted with Epi Info sta-
tistical software, version 6.03, Centers for Disease Control
and Prevention, Atlanta, GA). 
Of the 444 nonreplicate imipenem-resistant P. aerugi-
nosa isolates collected in 2001, a total of 89 were random-
ly selected and analyzed for acquired MBL genes of the
blaIMP and blaVIM types in dot-blot hybridization experi-
ments carried out with purified genomic DNAspotted (0.5
µg per spot) on positively charged nylon membranes
(ZetaProbe, Bio-Rad, Hercules, CA) with digoxygenin-
labeled DNA probes. The probes were polymerase chain
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Siena, Italy reaction amplicons containing internal fragments of the
blaIMP-1 (754–1,114 nt, EMBL/GenBank database entry
S71932) or of the blaVIM-1 gene (3,366–3,888 nt,
EMBL/GenBank database entry Y18050), respectively
obtained using primers IMP-DIA (forward, 5′-GGAATA-
GAGTGGCTTAATTCTC; reverse, 5′-GTGATGCGTCY-
CCAAYTTCACT) and VIM-DIA (forward, 5′-CAGA
TTGCCGATGGTGTTTGG; reverse, 5′-AGGTGGGC-
CATTCAGCCAGA) as described previously (13).
Hybridization was carried out under conditions that
allowed recognition, by each probe, of different allelic
variants of the corresponding MBL determinant. None of
the imipenem-resistant isolates were recognized by the
blaIMP probe, while 64 (72%) were recognized by the
blaVIM probe. In the 64 blaVIM-positive isolates, the nature
of the determinant was further investigated by analysis of
the RsaI restriction fragment length polymorphism of the
gene region amplified by the VIM-DIA primers as
described previously. With this approach, the determinant
was identified as blaVIM-1-like in 54 isolates (84%), and as
blaVIM-2-likein the remaining 10 isolates (16%). 
The sources of the 64 blaVIM-positive isolates were 52
inpatients from 15 different wards (including 10 medical
wards, 4 surgical wards, and an intensive care unit), 5
patients from 4 different long-term care facilities for elder-
ly persons, and 7 outpatients (Table 1). The degree of
genomic relatedness of these isolates was investigated by
Random Amplification of Polymorphic DNA(RAPD) (14)
and by Amplified Fragment Length Polymorphism
(AFLP) (15). Electrophoretic profiles generated by the
techniques described earlier were compared by the
GelComparII software (Applied Maths, Kortrijk,
Belgium). Consistent results were obtained with both typ-
ing methods. Isolates sharing a Dice similarity coefficient
>0.88 comparing their RAPD-profiles were assigned to the
same cluster. Results of molecular typing indicated that
most blaVIM-positive isolates (61 [95%]) belonged to either
of two clusters, indicated as cluster A and B respectively,
while the remaining three isolates were unrelated with
those clusters and also among each other (Figure). Cluster
Aincluded 53 isolates, all containing blaVIM-1-like determi-
nants. They were widely distributed in the hospital (15
wards), and were also found in three long-term care facili-
ties and in six outpatients. Cluster B included eight iso-
lates, all containing blaVIM-2-like determinants. The
isolates were from four wards where isolates of cluster A
had also been detected. Of the three sporadic isolates, one
(carrying a blaVIM-2-like gene) was from a ward where iso-
lates of clusters Aand B had also been detected, the second
(also carrying a blaVIM-2-like gene) was from a long-term
care facility different from those yielding isolates of clus-
ter A, and the third (carrying a blaVIM-1-like gene) was from
an outpatient (Table 1). Genotyping of the 25 blaVIM-nega-
tive isolates indicated that 5 belonged in cluster A, 1 in
cluster B, while the remaining 19 were unrelated to the
VIM producers and were overall distributed among 6 dif-
ferent genotypes (Table 1).
Imipenem MICs for the blaVIM-positive isolates were
always >64  µg/mL (range 64–512 µg/mL), while being
always <64 µg/mL for the hybridization-negative isolates.
Most of the blaVIM-positive isolates (49 of 64 [76%]) exhib-
ited a multidrug-resistant phenotype including all the tested
drugs (imipenem, meropenem, ceftazidime, piperacillin,
aztreonam, amikacin, gentamicin, tobramycin, and
ciprofloxacin), except polymixin B. On the other hand, this
virtually panresistant phenotype was observed in 7 (28%)
of 25 blaVIM-negative isolates (Table 2).
Conclusions
Our findings are of concern since they demonstrate that
acquired MBLs can rapidly emerge and become a major
cause of broad-spectrum β-lactam resistance among noso-
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Table 1. Genetic relatedness, presence of MBL determinants, and distribution of the 89 imipenem-resistant Pseudomonas aeruginosa 
isolates
a 
No. of isolates  RAPD–AFLP genotypes
b  blaVIM allele  Hospital wards (patients)  Long-term care facilities (patients)  Outpatients 
blaVIM-positive           
53  A  blaVIM-1-like  15 (43)  3 (4)  6 
8  B  blaVIM-2-like  4
c (8)  -  - 
1  C  blaVIM-2-like  1
d (1)  -  - 
1  D  blaVIM-2-like  -  1 (1)  - 
1  E  blaVIM-1-like  -  -  1 
blaVIM-negative           
5  A  None  2 (3)  -  2 
1  B  None  1 (1)  -  - 
19  F-G-H-I-J-K
e  None  8 (16)  1 (1)  2 
a MBL, metallo-β-lactamase. 
bRAPD–AFLP, Random Amplification of Polymorphic DNA–Amplified Fragment Length Polymorphism. Results obtained with the two genotyping techniques were 
always consistent with each other. 
cIn these wards isolates of cluster A were also detected.  
dIn this ward isolates of clusters A and B were also detected. 
eGenotypes F to K included a number of isolates ranging from 1 to 7.  comial pathogens. In our setting blaVIM-positive P. aerugi-
nosa isolates, which were sporadically detected for the
first time in 1999 (12), represented approximately 20% of
all  P. aeruginosa isolates and 70% of the carbapenem-
resistant P. aeruginosa isolates, respectively, during 2001.
These figures exceed those reported for MBL producers
from other settings (7,9,10). As an additional matter of
concern, the blaVIM-positive isolates were significantly
more resistant than the blaVIM-negative isolates to non-β-
lactam antimicrobial agents as well. 
In this survey, the blaVIM-positive isolates were detect-
ed on a regular basis during the year and appeared to be
widely distributed in the hospital and even outside of it.
Molecular characterization showed the simultaneous cir-
culation of different blaVIM alleles (either blaVIM1-like or
blaVIM-2-like) in multiple P. aeruginosa clones. Overall,
these findings suggest that blaVIM determinants have rapid-
ly established a condition of high-level endemicity in this
area. To the best of our knowledge, this study is the first in
which a similar condition has been reported. Even the large
outbreak reported in Greece was caused by a single clone
and was apparently confined to the hospital wards (11).
The finding of blaVIM-negative  P. aeruginosa isolates
showing the same genotype as that of the two major clus-
ters of blaVIM-positive strains suggests a likely acquisition
of the MBL determinants by strains already endemic in
this area, followed by clonal expansion of the blaVIM-posi-
tive strains. 
The possibility that spreading transferable MBL genes
among nosocomial gram-negative pathogens could emerge
as a major problem in the clinical setting underscores the
need for systematic surveillance of these resistance deter-
minants. Considering that MBLproducers were also isolat-
ed from outpatients and from long-term care facility
patients, even if all of them showed at least one hospital
treatment during the 6 months before, surveillance should
not be restricted to nosocomial isolates but should also
include isolates from community-acquired infections.
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